FCE 28260, A New 5α-Reductase Inhibitor: In Vitro and In Vivo Effects

    D. Giudici, G. Briatico, C. Cominato, T. Zaccheo, Catherine Iehlé, Marcella Nesi, A. Panzeri, E. Di Salle
    Image of study
    TLDR FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
    In the 1996 study, FCE 28260 was found to be a potent inhibitor of 5α-reductase, more effective than finasteride, a reference compound, in both in vitro and in vivo settings. FCE 28260 demonstrated lower IC50 values, indicating stronger inhibitory effects on the enzyme, and was more potent in inhibiting human recombinant 5αR type 1 and type 2 isozymes. In vivo, it reduced ventral prostate growth in castrated rats more effectively than finasteride and showed a longer-lasting reduction in prostatic DHT concentrations. The study, which involved six to seven rats per group for each dosing experiment, concluded that FCE 28260 could be a more effective treatment for conditions like benign prostatic hyperplasia and potentially androgenic alopecia due to its stronger and longer-lasting inhibition of 5αR.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results

    Related Community Posts Join

    2 / 2 results
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 2 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Related Research

    2 / 2 results